Wednesday 19 February 2020

Hepatitis Diagnostic Test Market is Projected to Register 6.5% CAGR till 2025

The global Hepatitis Diagnostics Market is expected to reach USD 6.9 billion by 2025, according to a new report by Grand View Research, Inc. In the past decade, the burden of hepatitis A, B & C has significantly increased compared to that of type D & E. In addition, in emerging countries, around 90% of the children (below 10 years of age) are infected with type A virus as stated by the WHO reports. These reports also state that in 2016, around 71 million people were affected by the hepatitis C and 257 million people were suffering from type B infection.
The non-government and government organizations play a vital role in increasing awareness of infectious diseases by conducting campaigns in order to deliver correct knowledge about the symptoms, condition, and detection techniques. Thereby, rendering a positive impact on the market growth owing to rising demand for diagnostic tests. Furthermore, the adoption of molecular biology techniques and other technologically advanced detection techniques are spurring the market growth.
Further key findings from the study suggest:
  • The blood tests segment dominate the market and is expected to exhibit the fastest growth rate over the forecast period owing to their higher adoption as a first line of diagnosis.
  • The liver function tests, sub type of blood test hold a significant share of the market since these tests are the first line diagnostics and are prerequisite for further analytical examinations required to performed for confirmation of virus causing the disease
  • North America dominated with largest revenue share in 2016, owing to rising prevalence, various government initiatives creating awareness regarding rising incidences, and highly developed healthcare infrastructure
  • Constant rise in the new cases of hepatitis is observed in Asia Pacific. Thus, this region is expected to witness a rapid growth during the forecast period.
  • Some of the major players competing include, but are not limited to Abbott Laboratories; Danaher Corporation; F. Hoffmann Roche; DiaSorin S.p.A; MedMira, Inc.; Siemens Ag, bioMeriuex SA; Hologic, Inc.; and Bio Rad Laboratories.
  • These players dominate the market with their strong brand identity and extensive geographic reach by their strategic initiatives such as mergers & acquisition and partnership with other players.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James

Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email:
sales@grandviewresearch.com
For More Information:
https://www.grandviewresearch.com

No comments:

Post a Comment

Insulin Delivery Devices Market To Reach $28.06 Billion By 2030

  The global  Insulin Delivery Devices Market  size was estimated at USD 28.06 billion in 2030 and is expected to grow at a CAGR of 7.89% fr...